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Early LVEF recovery as indicated by a gain >10% between post- (day 7) and pre-opera-
tive values was documented in 55/136 post-operative survivors. Multivariate analysis
showed that pre-operative CTR>0.60 (p=0,006) and the mean gradient (p=0,045), were
independent predictors of early LVSD reversibility.
During a mean follow-up [FU] time of 4,6±3 yrs, 50 (36%) pts died, 70 % from non-car-
diac cause. In multivariate analysis 3 independent predictors of postoperative mortality
were found: diabetes (p=0,003), age >75 yrs (p=0,004) and the absence of early LVEF
recovery (p=0,01). Additionally, the postoperative functional benefit was significantly
greater in pts with LVEF recovery.Conclusion: Despite a relatively high but acceptable
peri-operative mortality rate, the benefit of AVR in AS with severe LVSD is clearly impor-
tant. Early post-operative LVEF recovery is associated with significantly better outcome
regarding both symptoms and survival.
1125-137 Progression of Ascending Aortic Dilatation in 
Congenital Bicuspid Aortic Valve Patients: Assessment 
by Serial Magnetic Resonance Imaging
Benjamin Atkeson, Gian Novaro, Michael Lieber, Richard Grimm, Brian Griffin, Richard D 
White, Cleveland Clinic Foundation, Cleveland, OH
Progression of Ascending Aortic Dilatation in Congenital Bicuspid Aortic Valve Patients:
Assessment by Serial MRI.
Introduction – Congenital bicuspid aortic valve (BAV) patients have an associated aortop-
athy, with ascending aortic dilatation and increased risk of dissection. Data is limited
regarding the rates of dilatation in these patients.
Methods – We identified consecutive adult patients with a diagnosis of BAV, who under-
went serial magnetic resonance imaging (MRI) of the aorta, at least 12 months apart.
Patients with prior aortic valve surgery were excluded. Demographic and echocardio-
graphic data, including beta blocker use was obtained by chart review. Aortic measure-
ments were made at the level of the sinuses and mid-ascending aorta.
Results – 66 BAV patients were identified (80% male; mean age 53 yrs). Mean follow-up
was 32 months (range 12-96). The mean annualized increase in aortic dilatation at the
sinuses was .8 mm/yr. Those with aortic regurgitation showed increased rates of dilata-
tion compared to those with normal and stenotic BAV(p=.05). No association was noted
between beta blocker use and rates of dilatation.
Conclusions- BAV patients have aortic dilatation, irrespective of valve dysfunction. In this
cohort BAV patients assessed by MRI, the average rates of ascending aortic dilatation
was 0.8mm/yr at the level of the sinuses, which is similar to prior reports. Those with aor-
tic regurgitation appear to have greater rates of progression, and may require closer
serial follow-up.
1125-138 N-Terminal Pro-Braintype Natriuretic Peptide in Patients 
With Aortic Valve Disease: Correlation to Surgical 
Result
Michael W. Weber, Roman Arnold, Matthias Rau, Christian Maikowski, Eva Keil, Roland 
Brandt, Vesselin Mitrovic, Christian Hamm, Kerckhoff Heart Center, Bad Nauheim, 
Germany
Background: The neurohormon NT-proBNP is secreted from the myocardium in
response to an increased left ventricular wall stress. As we have shown previously, NT-
proBNP is elevated in patients with aortic valve disease closely linked to disease severity
and clinical symptoms.
Hypothesis: Since NT-proBNP is elevated in patients with aortic stenosis (AS) and aortic
regurgitation (AR) it should decrease after successful aortic valve replacement (AVR) but
not in conservatively treated patients.
Methods: 92 patients (55 male; aged 67±11 years; EF>45%) with AS, AR or prior AVR
were included in the present study. Clinical symptoms, NT-proBNP and transaortic pres-
sure gradient (PG mean) were assessed at baseline and at follow up (9,9±0,6 months).
Values are given as mean±SD or SEM.
Results: AS was present in 64 patients (37 male, aged 69±11 years), AR in 17 patients
(10 male, aged 60±11 years), prior AVR in 11 patients (8 male, aged 67±7 years). 48
patients (40 AS, 8 AR) were surgically treated (AVR) and 44 patients (11 after prior AVR,
9 AR and 24 AS) were treated conservatively. NT-proBNP decreased remarkably in surgi-
cally treated patients with AS (3112±646 pg/ml to 845±175 pg/ml; p<0,01) and in patients
with AR (1575±861 pg/ml to 497±137 pg/ml; p < 0,01).There was no change in NT-
proBNP in conservatively treated patients with AS (885±293 pg/ml to 808±226 pg/ml;
ns), with AR (from 221±45 pg/ml to 484±276 pg/ml; ns) and in patients after prior AVR
(from 464±117 pg/ml to 745±226 pg/ml; ns). In patients with an improvement in clinical
symptoms (n=47) (at least one NYHA class) NT-proBNP decreased (2710±572 pg/ml to
912±178 pg/ml; p<0,01) whereas in patients with unchanged symptoms (n=25) NT-
proBNP levels did not change (574±132 pg/ml to 515±104 pg/ml; ns). In patients with a
worsening of clinical symptoms (n=15) NT-proBNP showed a tendency towards an
increase (478±163 pg/ml to 677±224 pg/ml; ns).
Conlusions: NT-proBNP is elevated in patients with aortic valve disease (AS and AR)
and decreases remarkably after successful surgical treatment closely linked to an
improvement in clinical symptoms. This underlines the usefulness of NT-proBNP as a
biochemical marker for the evaluation and monitoring of disease progression.
1125-139 Populations Benefiting From the Ross Procedure: A 
Long-Term Follow-Up
Pablo Stutzbach, Santiago Lynch, Pablo Roura, Alejandro Machaín, Roberto R. Favaloro, 
Institute of Cardiology and Cardiovascular Surgery of the Favaloro Foundation, Buenos 
Aires, Argentina
Background: The Ross procedure (RP) is a surgical alternative to mechanical prosthe-
ses or to bioprostheses for the treatment of aortic valve disease. However, not all patients
benefit from RP. The purpose of this study was to analyze the results at 90 months in
patients undergoing RP and to determine what populations were the most benefited.
Methods: From 1995 through 2003, 125 patients (mean age 38±13 years, 99 males)
underwent RP. Fifty-nine patients (47%) had severe aortic stenosis, 57 patients (46%)
had significant aortic regurgitation, 4 patients (3.2%) had active endocarditis, and 6 (5%)
patients had prosthetic dysfunction. Eighty-two patients (65%) had bicuspid aortic valve.
Pulmonary autograft and pulmonary homograft dysfunction was defined as >++/4 regur-
gitation or peak gradient >20 mmHg as registered by Doppler echocardiography.
Results: Hospital mortality was 3.2% (4 patients). Survival at 90 months was 96.3±1.8%.
Freedom from reoperation was 95.4±2.7%; from autograft explant, 97%±2.7%; from pul-
monary homograft explant, 99±1.3%; from autograft dysfunction, 87±3.6%; from pulmo-
nary homograft dysfunction, 73±7.2%; from endocarditis, 99±1.1%; and from
thromboembolism and bleeding, 100%. Patients with aortic valve regurgitation had a
higher tendency toward autograft dysfunction than patients with aortic stenosis (78±8%
versus 100%, P=.004).Patients with age <30 years had a higher tendency toward pulmo-
nary homograft dysfunction than patients with age >30 years (69±10% vs 90±5%
P=.001).On multivariate analysis (Cox test) no variables associated with mortality and
reoperation. However, previous aortic regurgitation associated with autograft dysfuntion
(OR 5.4, 95% CI 1.21-24.8, P=.027), and age <30 years (OR 0.9, 95% CI 0.86-0.95,
P=.001), with homograft dysfunction.
Conclusion: RP constitutes an alternative for patients with aortic valve stenosis and age
>30 years, since they present with a low rate of events at 90 months.
1125-140 Creases and Folds: Why Does the Bicuspid Aortic Valve 
Fail So Early?
Francis Robicsek, Mano J. Thubrikar, Joseph W. Cook, Mark K. Reames, Sr., Brett L. 
Fowler, Carolinas Heart Institute at Carolinas Medical Center, Charlotte, NC, Heineman 
Medical Research Laboratories, Carolinas Medical Center, Charlotte, NC
Background:Congenitally bicuspid aortic valves (CBAV) are the leading cause of clini-
cally manifest aortic valve disease in patients below the age of 50. The reason why
CBAV’s fail, however, has not been determined.
Methods: The subject has been investigated in vitro experiments as well as in computer-
digital simulation studies. Aortic roots containing bicuspid valve were obtained out of
young individuals who died of non-cardiac causes and had no clinically manifest aortic
valve disease. The specimens were freeze-dried shortly after death then thawed and
mounted in left heart simulator primed with glycerol solution and/or normal saline. Hemo-
dynamic parameters were monitored under different flow and pressure conditions. Valve
function was recorded and studied with both normal speed and with 800-frames/sec. cin-
ematography. Using the molds as a basis, morphology of the aortic root was recon-
structed by digital modeling and studied under different simulated conditions. Stress-
grids were constructed and stress was measured simulating function. The results of the
experiments were compared to those we have obtained in previous studies on the normal
tricuspid aortic valve.
Results: The principal findings are as follows:
1.  All congenitally bicuspid aortic roots are morphologically significantly stenotic 
even in absence of clinical symptoms and measurable pressure gradients.
1.  Congenitally bicuspid aortic valves show significant degree of creasing and 
folding even when fully expanded. This phenomenon further increases dur-
ing function.
1.  Contrary to the normal, tri-leaflet aortic valve, the folding of the leaflet edges of 
the CBAV is maximal in diastole, thus the diastolic pressure load exerted 
upon it is multiple of the normal.
Conclusions: The above phenomenon induces a significant stress overload, which 
undoubtedly contributes to the early failure rate of CBAV’s. 
Rates of Aortic Dilatation by Valvular Lesion
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